{"id":"W2734872002","doi":"10.1200/jco.2017.35.15_suppl.tps3101","title":"A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"","keywords":"Medicine; Tolerability; CD47; Immune checkpoint; Blockade; Immune system; Cancer research; Immunology; Internal medicine; Receptor; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001196357,0.002217166,0.001819848,0.0005514993,0.0005260151,0.0009124459,0.0007948633,0.001581655,0.003857745],"category_scores_gemma":[0.0007220116,0.0007510834,0.0009819827,0.0003610515,0.0009592299,0.0009608411,0.0003633694,0.002942055,0.001112206],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009987835,"about_ca_system_score_gemma":0.001381874,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001102232,"about_ca_topic_score_gemma":0.002872098,"domain_scores_codex":[0.9996508,0.0001317987,0.00001328957,0.00008755814,0.00003034748,0.00008606292],"domain_scores_gemma":[0.9994127,0.00007756267,0.0001317384,0.00005157995,0.00004542626,0.0002810001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7974964,0.09234095,0.00420584,0.0005886252,0.0007709166,0.0002363487,0.0003183973,0.001894209,0.04802123,0.0002471661,0.00285385,0.05102602],"study_design_scores_gemma":[0.5344065,0.4520916,0.008252808,0.00002302356,0.0002789366,0.0001559839,0.00005275707,0.000863769,0.002278978,0.0001932007,0.001377074,0.00002541634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931375,0.0008057926,0.0003860099,0.00036192,0.000119637,0.002911218,0.0008651338,0.000108866,0.001303829],"genre_scores_gemma":[0.9880782,0.0009625349,0.001415741,0.0008391605,0.0001607073,0.003924943,0.001711933,0.00003262259,0.002874243],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003857745,"threshold_uncertainty_score":0.01290542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08247291652155142,"score_gpt":0.4128003983709206,"score_spread":0.3303274818493692,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}